Non-small cell lung cancer · 13 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Docetaxel (DC) and Durvalumab Variant #01 | — | R 69 036 | 21d | — | — | ~3 | ~R 141 256 indirect | — |
Carboplatin and Pemetrexed Variant #01 | EGFR | R 14 563 | 21d | ~5.6 mo | ~13.8 mo | ~6 | ~R 87 376 PFS proxy · indirect | 25 |
Cisplatin and Pemetrexed Variant #01 | EGFR | R 13 666 | 21d | ~5.6 mo | ~14.1 mo | ~7 | ~R 95 222 PFS proxy · indirect | 25 |
MIC Variant #01 | — | R 8 193 | 21d | — | 31.5 mo | 4 | R 32 771 PFS proxy | 1 |
Cisplatin and Gemcitabine (GC) Variant #01 | — | R 3 933 | 21d | 48.0 mo | 93.6 mo | 6 | R 23 595 PFS proxy | — |
Cisplatin and Vinorelbine (CVb) Variant #01 | — | R 3 333 | 21d | — | — | 7 | R 13 269 PFS proxy | 1 |
Cisplatin and Docetaxel (DC) Variant #05 | — | R 3 185 | 21d | — | — | 3 | R 9 556 PFS proxy | 1 |
Carboplatin and Paclitaxel (CP) and Nivolumab Variant #01 Partial | — | R 2 645 | 21d | — | — | 13 | R 10 579 PFS proxy | 2 |
Cisplatin and Docetaxel (DC) and Nivolumab Variant #01 Partial | — | R 2 389 | 21d | — | — | 3 | R 7 167 PFS proxy | 1 |
Cisplatin and Etoposide (EP) Variant #22 | — | R 1 819 | 21d | — | ~7.6 mo | ~4 | ~R 7 277 PFS proxy · indirect | 1 |
Cisplatin and Vinorelbine (CVb) and Nivolumab Variant #01 Partial | — | R 1 356 | 21d | — | — | 3 | R 4 069 PFS proxy | 1 |
Carboplatin and Paclitaxel (CP) Variant #02 | — | R 1 025 | 21d | — | — | 18 | R 18 445 PFS proxy | 2 |
No neoadjuvant therapy Partial | — | — | — | 26.4 mo | 48.0 mo | — | — | 2 |
13 of 13 regimens shown